Hostname: page-component-8678677fb7-glxkz Total loading time: 0 Render date: 2026-10-22T13:20:22.405Z Has data issue: false hasContentIssue false
  • English
  • Français

The Emerging Infectious Challenge of Clostridium difficile-Associated Disease in Massachusetts Hospitals: Clinical and Economic Consequences

Published online by Cambridge University Press:  02 January 2015

Judith A. O'Brien ,
Betsy J. Lahue ,
J. Jaime Caro  and
David M. Davidson
Judith A. O'Brien*
Affiliation:
Caro Research Institute, Concord, Massachusetts
Betsy J. Lahue
Affiliation:
Genzyme Corporation, Cambridge, Massachusetts
J. Jaime Caro
Affiliation:
Caro Research Institute, Concord, Massachusetts Division of General Internal Medicine and Department of Epidemiology, Biostatistics and Occupational Medicine, McGill University, Montreal, Canada
David M. Davidson
Affiliation:
Genzyme Corporation, Cambridge, Massachusetts
*
Caro Research Institute, 336 Baker Avenue, Concord, MA 01742 (jobrien@caroresearch.com)
Get access ImageRights & Permissions [Opens in a new window]

Abstract

Objective.

To estimate the clinical and economic burden of Clostridium difficile-associated disease (CDAD) in Massachusetts over 2 years.

Design.

A retrospective analysis of Massachusetts hospital discharge data from 1999-2003 was conducted. Cases of CDAD in 2000 were identified using code 008.45 from the International Classification of Diseases, Ninth Revision, Clinical Modification; patients were excluded if they had a hospitalization in the prior year during which a diagnosis of CDAD was recorded. Hospitalizations for CDAD during 2001 and 2002 were examined. For primary case patients (ie, those for which CDAD was the principal diagnosis), all inpatient costs were deemed to be related, whereas for secondary case patients, all-patient refined diagnosis-related group assignment, case severity level, and length of stay (LOS) were used to calculate incremental costs attributable to CDAD. Costs were adjusted to the national level and reported in 2005 US dollars.

Results.

The CDAD cohort consisted of 3,692 patients; 59% were women, and the mean age was 70 years. This group represented 1% of all patients hospitalized in Massachusetts in 2000 (96% of hospitals treated at least 1 case; range, 1-257 cases). Of patients who received a first hospital diagnosis of CDAD in 2000, a total of 28% were primary case patients; their mean LOS was 6.4 days, and the mean cost per stay was $10,212. For secondary case patients, the mean CDAD-related incremental LOS was 2.95 days, and the mean incremental cost per stay was $13,675 per patient. Of patients with CDAD who survived their index stay in 2000, a total of 455 (14%) had at least 1 readmission for CDAD within the subsequent 2 years (mean number of readmissions, 1.4 per patient; range, 1-7 readmissions), with a mean time to first readmission of 3 months. Over 2 years, a total of 55,380 inpatient-days and $51.2 million were consumed by CDAD management.

Conclusion.

CDAD is widespread in Massachusetts hospitals. Rehospitalization with CDAD, if it occurs, generally happens within a few months and happens multiple times for some patients. Based on this study's findings, a conservative estimate of the annual US cost for CDAD management is $3.2 billion dollars.

Information

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 28 , Issue 11 , November 2007 , pp. 1219 - 1227
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Centers for Disease Control. Clostridium difficile information for healthcare providers. August 2004. Available at: http://www.cdc.gov/ncidod/dhqp/id_Cdiff.html. Accessed July 9, 2005.Google Scholar
2.Pothoulakis, C, LaMont, JT. Clostridium difficile colitis and diarrhea. Gastroenterol Clin North Am 1993;22:623–637.CrossRefGoogle ScholarPubMed
3.Hogenauer, C, Hammer, HF, Krejs, GJ, Reisinger, EC. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998;27:702–710.CrossRefGoogle ScholarPubMed
4.Gerding, DN, Johnson, S, Peterson, LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459–477.Google Scholar
5.Mylonakis, E, Ryan, ET, Calderwood, SB. Clostridium difficile-associated diarrhea. Arch Intern Med 2001;161:525–533.CrossRefGoogle ScholarPubMed
6.Rubin, MS, Bodenstein, LE, Kent, KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995;38:350–354.Google Scholar
7.Olson, MM, Shanholtzer, CJ, Lee, JT Jr, Gerding, DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994;15:371–381.CrossRefGoogle ScholarPubMed
8.Samore, MH, DeGirolami, PC, Tlucko, A, Lichtenberg, DA, Melvin, ZA, Karchmer, AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994;18:181–187.Google Scholar
9.McCarter, MD, Abularrage, C, Velasco, FT, Davis, JM, Daly, JM. Diarrhea and Clostridium difficile-associated diarrhea on a surgical service. Arch Surg 1996;131:1333–1337.Google Scholar
10.Loo, VG, Poirier, L, Miller, MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.Google Scholar
11.McDonald, LC, Owens, M, Jernigan, DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409–415.CrossRefGoogle ScholarPubMed
12.Miller, MA, Hyland, M, Ofner-Agostini, M, Gourdeau, M, Ishak, M for the Canadian Hospital Epidemiology Committee, the Canadian Nosocomial Infection Surveillance Program. Morbidity, mortality, and healthcare burden of nosocomial Clostridium Difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137–140.Google Scholar
13.Centers for Disease Control and Prevention, Food and Drug Administration, National Institutes of Health. Report of the Emerging Clostridial Disease Workshop, May 11, 2006: Summary of Proceedings. Atlanta, GA: Department of Health and Human Services;2006.Google Scholar
14.Hirschhorn, LR, Trnka, Y, Onderdonk, A, Lee, MT, Platt, R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994;169:127–133.Google Scholar
15.Kyne, L, Merry, C, O'Connell, B, Keane, C, O'Neill, D. Community-acquired Clostridium difficile infection. J Infect 1998;36:287–288.Google Scholar
16.Stergachis, A, Perera, DR, Schnell, MM, Jick, H. Antibiotic-associated colitis. West J Med 1984;140:217–219.Google Scholar
17.Wilcox, MH, Spencer, RC. Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect 1992;22:85–92.Google Scholar
18.Kelly, CP, LaMont, JT. Clostridium difficile infection. Annu Rev Med 1998;49:375–390.Google Scholar
19.Fekety, R, McFarland, LV, Surawicz, CM, Greenberg, RN, Elmer, GW, Mulligan, ME. Recurrent Clostridium difficile diarrheas: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324–333.Google Scholar
20.McFarland, LV, Surawicz, CM, Rubin, M, Fekety, R, Elmer, GW, Greenberg, RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43–50.CrossRefGoogle ScholarPubMed
21.Tedesco, FJ, Gordon, D, Fortson, WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1985;80:867–868.Google Scholar
22.Massachusetts Fiscal Year 1999-2003 Acute Hospital Case Mix Data Bases, Level III (CD-ROM). Boston, MA: Massachusetts Division of Health Care Finance and Policy;2001-2005.Google Scholar
23.2001 International Classification of Diseases, Ninth Revision, Clinical Modification. Hart, A, Hopkins, CA, eds. Reston, VA: St. Anthony Publishing and West Valley City, UT: Ingenix;2000.Google Scholar
24.McDonald, LC, Colgnard, B, Dubberke, E, Song, X, Horan, T, Kutty, PK;Ad Hoc Clostridium difficile Surveillance Working Group. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28:140–145.Google Scholar
25.Palmore, TN, Sohn, S, Malak, SF, Eagen, J, Sepkowitz, KA. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005;26:680–684.Google Scholar
26. US Department of Labor, Bureau of Labor Statistics. Consumer price indexes. Available at: http://www.bls.gov/cpi/home.htm. Accessed July 14, 2005.Google Scholar
27.Office of Research, Development, and Information;Centers for Medicare and Medicaid Services. Medicare and Medicaid Statistical Supplement, 2002. Baltimore, MD: US Department of Health and Human Services;2004.Google Scholar
28.Kyne, L, Hamel, MB, Polavaram, R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346–353.CrossRefGoogle ScholarPubMed
29.McDonald, LC, Killgore, GE, Thompson, A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433–2441.CrossRefGoogle ScholarPubMed
30.McDonald, LC. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005;26:672–675.Google Scholar
31.Ohio Department of Health. Final report of rates of Clostridium difficile for Ohio hospitals January 1-December 31, 2006. July 28, 2006. Ohio Department of Health. Available at: http://www.odh.ohio.gov/ASSETS/5EA5D246A2AB47868F8C8D6CCAAFEBC/C%20diff%20Final%20Report03012007.pdf. Accessed October 2, 2007.Google Scholar
32.Connecticut Department of Public Health. Reportable disease and laboratory findings, 2006. Connecticut Epidemiologist 2006;26:1–4.Google Scholar
33.Miller, RR, Jick, H. Antibiotic-associated colitis. Clin Pharmacol Ther 1977;22:1–6.Google Scholar
34.Centers for Disease Control and Prevention. Severe Clostridium difficile-associated disease in populations previously at low risk—four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201–1205.Google Scholar
35.Musher, DM, Aslam, S, Logan, N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586–1590.Google Scholar
36.Pepin, J. Improving the treatment Clostridium difficile–associated disease: where should we start? Clin Infect Dis 2006;43:553–555.CrossRefGoogle ScholarPubMed
37.Buchner, AM, Sonnenberg, A. Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Dig Dis Sci 2002;47:201–207.Google Scholar
38.Pepin, J, Routhier, S, Gagnon, S, Brazeau, I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758–764.Google Scholar
39.O'Brien, JA, Patrick, AR, Caro, JJ. Costs of managing CAP are double for elderly patients. Drug Benefit Trends 2003;15:32–47.Google Scholar
40.HCUPnet, Healthcare Cost and Utilization Project. 2004 nationwide inpatient sample. Rockville, MD: Agency for Healthcare Research and Quality. Available at: http://hcupnet.ahrq.gov/.Google Scholar